The annual performance report of 2021 was released on January 20. With the sharp rise in the prices of Chinese herbal medicine raw materials, packaging materials and energy, the company has maintained the stability of business performance by continuously optimizing the production process, improving the accuracy of procurement, reducing costs, continuing to deepen marketing reform, and strengthening independent and joint research and development. In 2021, the company realized an operating income of 943 million yuan, a net profit attributable to shareholders of listed companies of 163 million yuan, and a basic earnings per share of 0.28 yuan. The company plans to distribute a cash dividend of 2.60 yuan (including tax) for every 10 shares.
In 2021, the epidemic of covid-19 pneumonia in China was effectively controlled, and the traditional Chinese medicine industry gradually recovered from the impact of the epidemic. In the face of the changing situation, the company focused on its main business, fully relied on the “two unique Swords”, strengthened R & D, continued to deepen marketing reform, comprehensively promoted fine management, and maintained the basic stability of overall performance during the shock period of marketing reform. During the reporting period, the company realized an operating revenue of 942.6746 million yuan, a year-on-year decrease of 6.30%; The net profit attributable to the shareholders of the listed company was 163.392 million yuan, a year-on-year decrease of 8.66%. The sales revenue of main core products remained basically stable, wohua? The sales revenue of Xinkeshu tablets decreased by 7.23% over the same period last year, the sales revenue of Gushukang capsules / granules decreased by 22.39% over the same period last year, the sales revenue of Hedan tablets / capsules increased by 5.82% over the same period last year, and the sales revenue of Naoxueshu oral liquid increased by 14.53% over the same period last year.
The announcement shows that since 2020, the prices of raw materials, packaging materials and energy of traditional Chinese medicine have continued to rise. In terms of traditional Chinese medicine, the prices of Rehmannia glutinosa, epimedium and leech increased by more than 350%, 160% and 100% respectively, and the prices of salt psoralen, Rhizoma Drynariae and peony bark also increased significantly. In the face of the rising cost of main raw materials, on the one hand, the company scientifically studies and judges the market situation, accurately predicts the price trend, makes a small number of dynamic purchases, expands the direct mining of origin and other measures, and flexibly combines them to minimize the procurement cost. On the other hand, the company continuously optimizes the production process to effectively reduce the cost of water, alcohol, steam and sewage treatment and product cost.
In 2021, Shandong Wohua Pharmaceutical Co.Ltd(002107) continued to increase R & D investment, deeply tap clinical value and continuously broaden and deepen the “moat” through quality control optimization, process and technology improvement, pharmacodynamic material basis and action mechanism research, clinical re evaluation, etc. In terms of independent research and development, in 2021, the company obtained four national invention patent certificates, such as “a method for determining the fingerprint of shenzhiling preparation” and “a method for determining the content of multiple effective components in Hedan tablets”. Wohua? The invention patent of Xinkeshu tablet “Application of traditional Chinese medicine composition in preparing drugs for treating anxiety and depression associated with coronary heart disease” was awarded the first prize of Weifang patent award in 2021. In terms of joint R & D, Shandong Wohua Pharmaceutical Co.Ltd(002107) 12 scientific research projects were successfully promoted during the year. Wohua during the reporting period? Xinkeshu tablet has changed from medical insurance class B to class A, which reflects the high recognition of product quality and curative effect by the state.
In 2021, Shandong Wohua Pharmaceutical Co.Ltd(002107) comprehensively and deeply promoted marketing reform and continued to increase investment in academic promotion. During the reporting period, 2491 Wuxi Online Offline Communication Information Technology Co.Ltd(300959) trainings, 3458 online academic activities and 3940 offline academic activities were held, with a significant improvement in quality and quantity compared with 2020. The company has made major adjustments to the staffing of the sales team, broken the geographical and variety restrictions, re divided the marketing management areas, and achieved good marketing results. The company’s leading product wohua? The sales of Xinkeshu tablets, Gushukang capsules / granules, Hedan tablets / capsules, Naoxueshu oral liquid and other products have increased significantly among similar products.
The company said that the economic situation will be severe and complex in 2022, and the industrial policy adjustment will be effectively implemented and show its power. The company will focus on the main business of R & D, production and sales of Chinese patent medicine, fully explore the potential of exclusive products, continue to further promote marketing reform, accelerate the construction of a marketing platform for multi variety coordinated development with “four exclusive medical insurance pillar products” as the core, and realize the stable and sustainable growth of sales revenue and profit.
